http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DK-174540-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-23 |
| filingDate | 1990-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2003-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa3e850b4e981b253f25d8989de69fe6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0dcf28aae6c0761ada823ac895cbb13 |
| publicationDate | 2003-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | DK-174540-B1 |
| titleOfInvention | Process for Preparing a Liquid Pharmaceutical Preparation Containing Calcitonin and Container Containing Such Preparation |
| abstract | Pharmaceutical compsns. for admin. intranasally, such as a liquid nasal spray, contain a calcitonin (I), a benzalkonium chloride and a suitable liquid diluent or carrier. (I) is derived from fish, esp. salmon or eels, humans, or pigs. That derived from salmon is preferred. The preferred concentration of the benzalkonium chloride is 0.003-0.03% w/v. Other materials that may be present include surfactants, preservatives, oiliary stimulants and pH regulators. The unit dose of (I) is 50-400 MRC units, given at a rate between once per day and 3 times per week. The total volume given per admin. is pref. between 0.05 and 0.15 ml. (I) is known for the treatment of Paget's disease, hypercalcaemia, and osteoporosis. Previously, (I) needed to be administered by injection, usually intramuscularly. This was painful and inconvenient since regular administration is necessary. The present compositions allow self-medication to take place. |
| priorityDate | 1982-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 56.